dalpiciclib + fulvestrant + letrozole + pyrotinib

This is a multi-drug combination regimen consisting of four agents used in the treatment of advanced or metastatic breast cancer, particularly in patients with hormone receptor-positive and/or HER2-positive disease. **Dalpiciclib** is an oral small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which blocks cell cycle progression from G1 to S phase, thereby inhibiting tumor cell proliferation[3][5]. **Fulvestrant** is a selective estrogen receptor degrader (SERD) that binds to estrogen receptors and accelerates their degradation, leading to downregulation of estrogen signaling. **Letrozole** is an aromatase inhibitor that suppresses estrogen synthesis by inhibiting the aromatase enzyme. **Pyrotinib** is an irreversible pan-ErbB tyrosine kinase inhibitor targeting HER1 (EGFR), HER2, and HER4 receptors; it blocks downstream signaling pathways involved in tumor growth[6][9][10]. This combination targets multiple oncogenic pathways—cell cycle regulation via CDK4/6 inhibition, hormonal signaling via ER antagonism/degradation and aromatase inhibition, and growth factor receptor signaling via pan-HER blockade—making it potentially effective against tumors with complex resistance mechanisms.

Brand names

Paudina

Other names

dalpiciclib + fulvestrant + letrozole + pyrotinib